Literature DB >> 31191854

Fluorine substituted methoxyphenylalkyl amides as potent melatonin receptor agonists.

Andrew Tsotinis1, Rodanthi Kompogennitaki1, Ioannis Papanastasiou1, Peter J Garratt2, Alina Bocianowska3, David Sugden3.   

Abstract

A series of fluorine substituted methoxyphenylalkyl amides were prepared with different orientations of the fluorine and methoxy groups with respect to the alkylamide side chain and with alkyl sides of differing lengths (n = 1-3). β-Dimethyl and α-methyl derivatives were also synthesised. The compounds were tested as melatonin agonists and antagonists using the pigment aggregation of Xenopus melanophores as the biological assay. A number of these compounds were potent melatonin agonists, the potency depending on the length of the alkyl chain, the orientation of the methoxy and fluorine substituents, the amide chain length and, for the ethyl side-chain analogues, the presence of β-substituents.

Entities:  

Year:  2019        PMID: 31191854      PMCID: PMC6530086          DOI: 10.1039/c8md00604k

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  38 in total

1.  Design of subtype selective melatonin receptor agonists and antagonists.

Authors:  D Sugden; L K Yeh; M T Teh
Journal:  Reprod Nutr Dev       Date:  1999 May-Jun

2.  The effects of low-dose 0.5-mg melatonin on the free-running circadian rhythms of blind subjects.

Authors:  Lisa M Hack; Steven W Lockley; Josephine Arendt; Debra J Skene
Journal:  J Biol Rhythms       Date:  2003-10       Impact factor: 3.182

3.  Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease.

Authors:  Zheng Feng; Chuan Qin; Yang Chang; Jun-tian Zhang
Journal:  Free Radic Biol Med       Date:  2005-09-07       Impact factor: 7.376

Review 4.  Melatonin, sleep, and circadian rhythms.

Authors:  Frank A J L Scheer; Charles A Czeisler
Journal:  Sleep Med Rev       Date:  2005-02       Impact factor: 11.609

5.  Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease.

Authors:  Rohita Sharma; Catherine R McMillan; Catherine C Tenn; Lennard P Niles
Journal:  Brain Res       Date:  2005-12-20       Impact factor: 3.252

6.  Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.

Authors:  J B Blair; D Kurrasch-Orbaugh; D Marona-Lewicka; M G Cumbay; V J Watts; E L Barker; D E Nichols
Journal:  J Med Chem       Date:  2000-11-30       Impact factor: 7.446

7.  Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles.

Authors:  R Faust; P J Garratt; R Jones; L K Yeh; A Tsotinis; M Panoussopoulou; T Calogeropoulou; M T Teh; D Sugden
Journal:  J Med Chem       Date:  2000-03-23       Impact factor: 7.446

Review 8.  An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease.

Authors:  M A Pappolla; Y J Chyan; B Poeggeler; B Frangione; G Wilson; J Ghiso; R J Reiter
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

9.  Effects of exogenous melatonin on sleep: a meta-analysis.

Authors:  Amnon Brzezinski; Mark G Vangel; Richard J Wurtman; Gillian Norrie; Irina Zhdanova; Abraham Ben-Shushan; Ian Ford
Journal:  Sleep Med Rev       Date:  2005-02       Impact factor: 11.609

10.  Melatonin does not "directly scavenge hydrogen peroxide": demise of another myth.

Authors:  Grant Fowler; Malgosia Daroszewska; Keith U Ingold
Journal:  Free Radic Biol Med       Date:  2003-01-01       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.